m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05108
 [1]
Non-coding RNA SNAI3-AS1 SND1  lncRNA       miRNA   circRNA Direct Inhibition m6A modification NFE2L2 NFE2L2 SND1 : m6A sites
m6A Modification:
m6A Regulator Staphylococcal nuclease domain-containing protein 1 (SND1) READER
 Regulator Info 
m6A Target Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator SNAI3 antisense RNA 1 (SNAI3-AS1) LncRNA View Details
Regulated Target Staphylococcal nuclease domain-containing protein 1 (SND1) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Mechanistically, SNAI3-AS1 competitively binds to SND1 and perturbs the m6A-dependent recognition of Nuclear factor erythroid 2-related factor 2 (NFE2L2) mRNA 3'UTR by SND1, thereby reducing the mRNA stability of Nrf2. Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m6A-dependent recognition of Nrf2 mRNA mediated by SND1
Responsed Disease Brain cancer ICD-11: 2A00
 Disease Info 
In-vitro Model
 U-87MG ATCC Glioblastoma Homo sapiens CVCL_0022
U-251MG Astrocytoma Homo sapiens CVCL_0021
A-172 Glioblastoma Homo sapiens CVCL_0131
LN-229 Glioblastoma Homo sapiens CVCL_0393
U-373MG ATCC Astrocytoma Homo sapiens CVCL_2219
T98G Glioblastoma Homo sapiens CVCL_0556
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model a total of 5 × 105 U87MG cells stably expressing firefly luciferase (Fluc) with indicated treatments were injected into the mouse brain at 2 mm lateral, 2 mm posterior to the bregma, and 2 mm depth via a stereotaxic apparatus.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Nuclear factor erythroid 2-related factor 2 (NFE2L2) 72 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Omaveloxolone Approved [2]
Synonyms
RJCWBNBKOKFWNY-HGNIWHNWSA-N; N-((4aR,6aR,6bS,12aS,14aR,14bR)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide; 1474034-05-3; AKOS030526563
    Click to Show/Hide
MOA Activator
External Link
CID: 71811910
TTD: D0JB3H
DrugBank: DB12513
 Compound Name SFX-01 Phase 2 [3]
MOA Activator
External Link
TTD: D02NMR
 Compound Name ABT-RTA-408 Phase 2 [4]
MOA Modulator
External Link
TTD: D0K7NI
 Compound Name OT-551 Phase 2 [5]
Synonyms
Tempol-H prodrug, Othera
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 10131000
TTD: D0P1IX
DrugBank: DB05650
 Compound Name OT551 Phase 2 [6]
MOA Activator
External Link
TTD: DHG2O3
 Compound Name CXA10 Phase 2 [7]
MOA Activator
External Link
TTD: DF1JO7
 Compound Name HPP971 Phase 1 [8]
Synonyms
ANT 401
    Click to Show/Hide
MOA Activator
External Link
TTD: D9ZEM7
 Compound Name Benzamide derivative 6 Patented [9]
Synonyms
PMID28454500-Compound-86
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 90448888
TTD: D00PGP
 Compound Name Benzo[d]oxazole derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-79
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 736095
TTD: D03RTM
 Compound Name PMID28454500-Compound-93 Patented [9]
MOA Inhibitor
External Link
CID: 77174
TTD: D04YKV
 Compound Name PMID28454500-Compound-92 Patented [9]
MOA Inhibitor
External Link
TTD: D05EMI
 Compound Name 4-(2-cyclohexylethoxy) aniline derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-89
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 15943058
TTD: D06KOH
 Compound Name Benzo[d]oxazole derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-80
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 650480
TTD: D07TEZ
 Compound Name Thiazole derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-84
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1383822
TTD: D0D8KO
 Compound Name Benzamide derivative 5 Patented [9]
Synonyms
PMID28454500-Compound-85
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0DE0Y
 Compound Name Benzo[d]oxazole derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-81
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0G8CF
 Compound Name Benzo[d]oxazole derivative 4 Patented [9]
Synonyms
PMID28454500-Compound-82
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 17609434
TTD: D0M2ZX
 Compound Name 4-(2-cyclohexylethoxy) aniline derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-88
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3365475
TTD: D0ND6T
 Compound Name PMID28454500-Compound-96 Patented [9]
MOA Inhibitor
External Link
CID: 2761171
TTD: D0O5ZK
DrugBank: DB00609
 Compound Name PMID28454500-Compound-94 Patented [9]
MOA Inhibitor
External Link
CID: 23527
TTD: D0P9ZD
 Compound Name PMID28454500-Compound-91 Patented [9]
MOA Inhibitor
External Link
TTD: D0PF4H
 Compound Name 4-(2-cyclohexylethoxy) aniline derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-87
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 2900 nM
External Link
CID: 15943048
TTD: D0R2AI
 Compound Name PMID28454500-Compound-95 Patented [9]
MOA Inhibitor
External Link
CID: 21450
TTD: D0RO7A
 Compound Name Thiazole derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-83
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 1298265
TTD: D0T2LN
 Compound Name 4-(2-cyclohexylethoxy) aniline derivative 4 Patented [9]
Synonyms
PMID28454500-Compound-90
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3886018
TTD: D0T7WW
 Compound Name PMID28454500-Compound-57 Patented [9]
MOA Inhibitor
Activity IC50 = 81 nM
External Link
CID: 135315519
TTD: D00TVL
 Compound Name PMID28454500-Compound-8 Patented [9]
MOA Activator
External Link
CID: 66546002
TTD: D01GTU
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 4 Patented [9]
Synonyms
PMID28454500-Compound-31
    Click to Show/Hide
MOA Activator
External Link
TTD: D01MZI
 Compound Name PMID28454500-Compound-36 Patented [9]
MOA Activator
External Link
CID: 121289252
TTD: D01PKZ
 Compound Name Naphthalene derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-62
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3294285
TTD: D02FWA
 Compound Name PMID28454500-Compound-58 Patented [9]
MOA Inhibitor
Activity IC50 = 84 nM
External Link
TTD: D02JFV
 Compound Name Chalcone derivative 4 Patented [9]
Synonyms
PMID28454500-Compound-19
    Click to Show/Hide
MOA Activator
External Link
CID: 118567653
TTD: D02SPI
 Compound Name 2-hydroxybenzamide derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-38
    Click to Show/Hide
MOA Activator
External Link
TTD: D02YNU
 Compound Name Vinyl sulfone derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-20
    Click to Show/Hide
MOA Activator
Activity EC50 = 530 nM
External Link
CID: 73053707
TTD: D04ILM
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-29
    Click to Show/Hide
MOA Activator
External Link
TTD: D06LEF
 Compound Name Diterpenoid derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-47
    Click to Show/Hide
MOA Activator
External Link
CID: 132210477
TTD: D09FZF
 Compound Name 1-phenyl-1,3,4-triazole derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-76
    Click to Show/Hide
MOA Inhibitor
Activity Kd = 23000 nM
External Link
CID: 74229666
TTD: D09MSN
 Compound Name PMID28454500-Compound-13 Patented [9]
MOA Activator
External Link
CID: 73335601
TTD: D0AJ2T
 Compound Name 1-phenyl-1,3,4-triazole derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-77
    Click to Show/Hide
MOA Inhibitor
Activity Kd = 17000 nM
External Link
CID: 1327659
TTD: D0AR0L
 Compound Name PMID28454500-Compound-12 Patented [9]
MOA Activator
External Link
TTD: D0AX4Q
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-28
    Click to Show/Hide
MOA Activator
External Link
TTD: D0AZ8T
 Compound Name PMID28454500-Compound-41 Patented [9]
MOA Activator
External Link
CID: 11000442
TTD: D0C1PB
 Compound Name Chalcone derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-17
    Click to Show/Hide
MOA Activator
External Link
CID: 118567519
TTD: D0EO3S
 Compound Name PMID28454500-Compound-34 Patented [9]
MOA Activator
External Link
CID: 121289250
TTD: D0FH6P
 Compound Name PMID28454500-Compound-33 Patented [9]
MOA Activator
External Link
CID: 121289344
TTD: D0FM3Q
 Compound Name Chalcone derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-18
    Click to Show/Hide
MOA Activator
External Link
TTD: D0G1LS
 Compound Name PMID28454500-Compound-50 Patented [9]
MOA Activator
External Link
CID: 193653
TTD: D0G4EK
DrugBank: DB04339
 Compound Name 1-phenyl-1,3,4-triazole derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-78
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 3071025
TTD: D0I2DV
 Compound Name PMID28454500-Compound-3 Patented [9]
MOA Activator
External Link
TTD: D0JH8Z
 Compound Name Pyridyl compound 1 Patented [9]
Synonyms
PMID28454500-Compound-15
    Click to Show/Hide
MOA Activator
External Link
TTD: D0KX0J
 Compound Name PMID28454500-Compound-32 Patented [9]
MOA Activator
External Link
CID: 121289291
TTD: D0L1JQ
 Compound Name PMID28454500-Compound-60 Patented [9]
MOA Inhibitor
Activity IC50 = 140 nM
External Link
TTD: D0LL7V
 Compound Name PMID28454500-Compound-40 Patented [9]
MOA Activator
External Link
CID: 5316743
TTD: D0MQ3X
 Compound Name 3-phenyl propanoic derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-68
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 61 nM; Kd = 59000 nM
External Link
TTD: D0MS7G
 Compound Name PMID28454500-Compound-35 Patented [9]
MOA Activator
External Link
CID: 121289348
TTD: D0MX0Q
 Compound Name PMID28454500-Compound-49 Patented [9]
MOA Activator
External Link
TTD: D0N1VC
 Compound Name PMID28454500-Compound-9 Patented [9]
MOA Activator
External Link
CID: 66546189
TTD: D0N9GH
 Compound Name PMID28454500-Compound-59 Patented [9]
MOA Inhibitor
Activity IC50 = 90 nM
External Link
TTD: D0O3KN
 Compound Name 3-phenyl propanoic derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-67
    Click to Show/Hide
MOA Inhibitor
Activity IC50 > 1000000 nM
External Link
CID: 4685764
TTD: D0O6LW
 Compound Name 3-phenyl propanoic derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-69
    Click to Show/Hide
MOA Inhibitor
Activity Kd = 1.3 nM
External Link
TTD: D0Q8JZ
 Compound Name Diterpenoid derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-48
    Click to Show/Hide
MOA Activator
External Link
CID: 132210549
TTD: D0Q9QQ
 Compound Name PMID28454500-Compound-11 Patented [9]
MOA Activator
External Link
CID: 68066028
TTD: D0RM4V
 Compound Name PMID28454500-Compound-37 Patented [9]
MOA Activator
External Link
CID: 121289347
TTD: D0SA1N
 Compound Name Chalcone derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-16
    Click to Show/Hide
MOA Activator
External Link
CID: 53262706
TTD: D0U9TR
 Compound Name Pyrazino[2,1-a]isoquinolin derivative 3 Patented [9]
Synonyms
PMID28454500-Compound-30
    Click to Show/Hide
MOA Activator
External Link
TTD: D0VA2G
 Compound Name 2-hydroxybenzamide derivative 2 Patented [9]
Synonyms
PMID28454500-Compound-39
    Click to Show/Hide
MOA Activator
External Link
TTD: D0VW9H
 Compound Name PMID28454500-Compound-10 Patented [9]
MOA Activator
External Link
CID: 68066062
TTD: D0WN1Y
 Compound Name 1,2,3,4-tetrahydroisoquinoline derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-61
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0WR1I
 Compound Name Trepenoid derivative 1 Patented [9]
Synonyms
PMID28454500-Compound-14
    Click to Show/Hide
MOA Activator
External Link
TTD: D0XL2V
 Compound Name CAT4001 Preclinical [3]
MOA Activator
External Link
TTD: D24EPJ
 Compound Name M102 Preclinical [10]
MOA Activator
External Link
TTD: DA85KQ
 Compound Name TFM735 Preclinical [11]
MOA Activator
External Link
TTD: DPJ05C
2A00: Brain cancer 53 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Zinostatin stimalamer Approved [12]
Synonyms
Smancs (TN)
    Click to Show/Hide
External Link
CID: 70682998
TTD: D0Z4PE
 Compound Name Motexafin gadolinium Approved [13]
Synonyms
Xcytrin; Gadolinium texaphyrin; GdT2B2; GD-Tex; Motexafin gadolinium (USAN); PCI-0120; Xcytrin (TN)
    Click to Show/Hide
External Link
CID: 158385
TTD: D05BJD
DrugBank: DB05428
 Compound Name Lomustine Approved [14]
Synonyms
Belustine; CCNU; CINU; Cecenu; CeeNU; Chloroethylcyclohexylnitrosourea; Lomustina; Lomustinum; Bristol Myers Squibb Brand of Lomustine; CCNU [Chloroethyl nitrosoureas]; Cyclohexyl chloroethyl nitrosourea; Lomustine medac Brand; Medac Brand of Lomustine; Rhone Poulenc Rorer Brand of Lomustine; OR5087; RB 1509; SRI 2200; Bristol-Myers Squibb Brand of Lomustine; CeeNU (TN); Lomustina [INN-Spanish]; Lomustinum [INN-Latin]; NPFAPI-06; Rhone-Poulenc Rorer Brand of Lomustine; CeeNU, CCNU, Lomustine; Lomustine (USAN/INN); Lomustine [USAN:BAN:INN]; N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea; (Chloro-2-ethyl)-1-cyclohexyl-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea; (Cloro-2-etil)-1-cicloesil-3-nitrosourea [Italian];1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea; 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea [Chloroethyl nitrosoureas]; 1-(2-Chloroethyl)-3-cyclohexylnitrosourea
    Click to Show/Hide
External Link
CID: 3950
TTD: D04JPJ
DrugBank: DB01206
 Compound Name Borocaptate sodium B 10 Approved [12]
External Link
TTD: D03EOT
 Compound Name DTI-015 Approved [15]
Synonyms
Carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Carmustin; Nitrumon; Carmubris; Gliadel; BiCNU; Bi CNU; Carmustinum; Bischlorethylnitrosurea; Bischlorethylnitrosourea; Carmustina; Becenun; Becenum; Bischloroethyl nitrosourea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bis(2-chloroethyl)nitrosourea; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; Gliadel Wafer; FDA 0345; Bischloroethylnitrosourea; SRI 1720; 1,3-Bis(2-chloroethyl)nitrosourea; BiCNU (TN); Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTI 015; NCI-C04773; SK; Injectable carmustine, Direct Therapeutics
    Click to Show/Hide
External Link
CID: 2578
TTD: D01OXI
DrugBank: DB00262
 Compound Name Prinomastat Approved [16]
Synonyms
AG-3354; AG-3362; Prinomastat (USAN/INN); (3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonylthiomorpholine-3-carboxamide
    Click to Show/Hide
External Link
CID: 466151
TTD: D00MDP
DrugBank: DB05100
 Compound Name INO-1001 Phase 3 [17]
Synonyms
Hypoxanthine arabinoside; LT00454797; 9-[(3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purin-6-one
    Click to Show/Hide
External Link
CID: 6708742
TTD: D0ZY3E
 Compound Name GliAtak Phase 3 [18]
Synonyms
GliAtak (TN)
    Click to Show/Hide
External Link
TTD: D0T3JF
 Compound Name SOT-107 Phase 3 [19]
Synonyms
TransMID
    Click to Show/Hide
External Link
TTD: D0QL4X
 Compound Name ICT-107 Phase 3 [20]
External Link
TTD: D0M1RD
 Compound Name Cintredekin besudotox Phase 3 [21]
External Link
TTD: D0G6RB
 Compound Name Rindopepimut Phase 3 [22]
External Link
TTD: D05FRP
 Compound Name DCVax-Ovarian Phase 3 [23]
Synonyms
DCVax-L; Dendritic cell-based immunotherapy (ovarian cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D02XEI
 Compound Name DCVax-Brain Phase 3 [24]
Synonyms
Dendritic cell-based immunotherapy (brain cancer), Northwest Biotherapeutics
    Click to Show/Hide
External Link
TTD: D02RED
 Compound Name TVI-Brain-1 Phase 2/3 [25]
External Link
TTD: D5A6JN
 Compound Name NLG8189 Phase 2/3 [26]
Synonyms
1-Methyl-D-tryptophan; Indoximod; 110117-83-4; D-Tryptophan, 1-methyl-; D-1MT; Indoximod (NLG-8189); D-1-methyltryptophan; UNII-TX5CYN1KMZ; D-(+)-1-Methyltryptophan; TX5CYN1KMZ; (R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methylindol-3-yl)propanoic acid; NSC-721782; (2R)-2-amino-3-(1-methyl-3-indolyl)propanoic acid; 1-MT; (2R)-2-azanyl-3-(1-methylindol-3-yl)propanoic acid; (2R)-2-amino-3-(1-methyl-1H-indol-3-yl)propanoic acid; D-l-Methyltryptophan; Indoximod [USAN:INN]; NLG-8189; NLG 8189
    Click to Show/Hide
External Link
CID: 405012
TTD: D0B5HS
DrugBank: DB12827
 Compound Name Synthetic survivin peptide vaccine Phase 2 [27]
External Link
TTD: DWZ02M
 Compound Name Fresolimumab Phase 2 [28]
Synonyms
GC-1008
    Click to Show/Hide
External Link
TTD: DB35WK
 Compound Name DNX-2401 Phase 2 [29]
Synonyms
Tasadenoturev
    Click to Show/Hide
External Link
TTD: D8SV9R
 Compound Name TVI-Brain-1 cancer vaccine Phase 2 [30]
External Link
TTD: D0ZR6E
 Compound Name PDT with Photofrin Phase 2 [26]
External Link
TTD: D0XL1T
 Compound Name F18-ML-10 Phase 2 [31]
External Link
TTD: D0K9NJ
 Compound Name PT2385 Phase 2 [32]
Synonyms
ONBSHRSJOPSEGS-INIZCTEOSA-N; PT-2385; UNII-6O16716DXP; 1672665-49-4; 6O16716DXP; SCHEMBL16555810; ZINC230453533; AKOS030526641; HY-12867; PT2385,1672665-49-4, PT 2385,PT-2385; Benzonitrile, 3-(((1S)-2,2-difluoro-2,3-dihydro-1-hydroxy-7-(methylsulfonyl)-1H-inden-4-yl)oxy)-5-fluoro-; 3-{[(1s)-2,2-Difluoro-1-Hydroxy-7-(Methylsulfonyl)-2,3-Dihydro-1h-Inden-4-Yl]oxy}-5-Fluorobenzonitrile; 3-(((1S)-2,2-Difluoro-1-hydroxy-7-methanesulfonyl-2,3-dihydro-1hinden-4-yl)oxy)-5-fluorobenzonitrile; 79A
    Click to Show/Hide
External Link
CID: 91754484
TTD: D0C9PZ
 Compound Name ABT-414 Phase 2 [33]
External Link
TTD: D06XIT
 Compound Name CLR1404-I-124 Phase 1/2 [34]
External Link
TTD: D06EWT
 Compound Name DM-CHOC-PEN Phase 2 [35]
External Link
CID: 16126905
TTD: D02ZZU
DrugBank: DB15075
 Compound Name L-alanosine Phase 2 [36]
Synonyms
SDX-102
    Click to Show/Hide
External Link
CID: 135409347
TTD: D02ELS
DrugBank: DB05540
 Compound Name APX005M Phase 2 [26]
External Link
TTD: D01ZLK
 Compound Name WP-1066 Phase 1/2 [30]
Synonyms
WP1066; 857064-38-1; (S,E)-3-(6-Bromopyridin-2-yl)-2-cyano-N-(1-phenylethyl)acrylamide; WP 1066; UNII-63V8AIE65T; 63V8AIE65T; AK-99218; C17H14BrN3O; (E)-3-(6-bromopyridin-2-yl)-2-cyano-N-[(1S)-1-phenylethyl]prop-2-enamide; MLS006010178; SCHEMBL1315826; QCR-16; SCHEMBL1315831; GTPL7972; CHEMBL1923234; EX-A760; AOB1497; DTXSID50235007; MolPort-044-723-708; MolPort-023-219-149; ZINC13983221; AKOS016007983; WP1066/WP-1066; CS-2736; DB12679; 2-Propenamide, 3-(6-bromo-2-pyridinyl)-2-cyano-N-((1S)-1-phenylethyl)-, (2E)-; HY-15312
    Click to Show/Hide
External Link
CID: 11210478
TTD: D0IV4C
DrugBank: DB12679
 Compound Name Anti-EGFRvIII CAR transduced PBL Phase 1/2 [37]
External Link
TTD: D08RJY
 Compound Name RG6156 Phase 1 [38]
External Link
TTD: DF8X5N
 Compound Name rhenium-186 Phase 1 [39]
Synonyms
(~186~Re)Rhenium; 14998-63-1; 186Re; DTXSID60933825; Q18882928; RHENIUM (186-RE); Rhenium Re-186; Rhenium, isotope of mass 186; Rhenium-186; RHENIUM-186 [WHO-DD]; UNII-ZU7F1ET6TM; ZU7F1ET6TM
    Click to Show/Hide
External Link
CID: 161105
TTD: DB7W8H
 Compound Name IGV-001 Phase 1 [40]
External Link
TTD: D9PM2E
 Compound Name DA-3607 Phase 1 [41]
Synonyms
Ad-stTRAIL; TRAIL adenoviral gene therapy (cancer), Dong-A
    Click to Show/Hide
External Link
TTD: D0V3ZX
 Compound Name DC/I540/KLH vaccine Phase 1 [42]
Synonyms
HTERT:540-548; Telomerase: 540-548 peptide vaccine; DC/I540/KLH vaccine (cancer); Dendritic cell/hTERT peptide I540/keyhole limpet hemocyanin vaccine, Dana-Farber; DC/I540/KLH vaccine (cancer), Dana-Farber
    Click to Show/Hide
External Link
TTD: D0RH3S
 Compound Name KX2-361 Phase 1 [43]
Synonyms
KX-02
    Click to Show/Hide
External Link
CID: 11545920
TTD: D0RE4L
 Compound Name MR1-1 Phase 1 [44]
Synonyms
MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX
    Click to Show/Hide
External Link
TTD: D0N3PC
 Compound Name INdoximod + temozolomide Phase 1 [30]
External Link
TTD: D0B8BY
 Compound Name Anti-CD133-CAR vector-transduced T cells Phase 1 [45]
External Link
TTD: D09HRH
 Compound Name 8H9 Phase 1 [46]
External Link
TTD: D06JAL
 Compound Name CC-8490 Phase 1 [47]
External Link
TTD: D03YGP
 Compound Name Sitimagene ceradenovec Discontinued in Phase 3 [48]
Synonyms
Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
    Click to Show/Hide
External Link
TTD: D0W8RX
 Compound Name Ranagengliotucel-T Discontinued in Phase 3 [49]
Synonyms
Glionix; Brain tumor vaccine, NovaRx; Antisense (TGFbeta) brain tumor vaccine, NovaRx
    Click to Show/Hide
External Link
TTD: D0N5AY
 Compound Name Oncolysin S Discontinued in Phase 2 [50]
Synonyms
N901-bR
    Click to Show/Hide
External Link
TTD: D0H0VW
 Compound Name Labradimil Discontinued in Phase 2 [51]
Synonyms
Cereport; Lobradimil; Receptor mediated permeabilizer; RMP 7; DRG-0182; RMP-7; N2-((S)-2-(L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolylglycyl-3-(2-thienyl)-L-alanyl-L-seryl-L-prolinamido)-3-(p-methoxyphenyl)propyl)-L-arginine; (S-(R*,R*))-L-Arginyl-L-prolyl-trans-4-hydroxy-L-prolyl-3-(2-thienyl)-L-alanylglycyl-L-seryl-N-(2-((4-((aminoiminomethyl)amino)-1-carboxybutyl)amino)-1-((4-methoxyphenyl)methyl)ethyl)-L-prolinamide
    Click to Show/Hide
External Link
CID: 6918284
TTD: D0G0IZ
DrugBank: DB06549
 Compound Name Brain tumor vaccine Discontinued in Phase 1 [52]
Synonyms
Brain cancer vaccine, IRC; Brain tumor vaccine, IRC; IR-850; Established cancer cell line therapy (brain cancer), IRC; GM-CSF vaccine (brain cancer), IRC
    Click to Show/Hide
External Link
TTD: D0JT1P
 Compound Name PCNU Terminated [53]
Synonyms
NSC-95466
    Click to Show/Hide
External Link
CID: 26328
TTD: D0JI5G
 Compound Name 131I-81C6 Terminated [54]
Synonyms
Neuradiab; MAb-81C6; Iodine-131-81C6; Astatine-211-MAb-81C6; Iodine-131-MAb-81C6; Iodine-131-ch-81C6; Iodine-131-ch-81C6-F(ab)2; 211At-MAb-81C6
    Click to Show/Hide
External Link
TTD: D07ZKK
 Compound Name NSD-551 Terminated [55]
Synonyms
BK channel activator (cancer), NeuroSearch/TopoTarget
    Click to Show/Hide
External Link
TTD: D03QTB
 Compound Name AGT-2000 Investigative [56]
Synonyms
Gene therapy (intravenous, brain cancer), ArmaGen
    Click to Show/Hide
External Link
TTD: D0C5WE
 Compound Name NV.XOD.09 Investigative [57]
External Link
TTD: D02RDC
 Compound Name EDP-19 Investigative [57]
Synonyms
SiRNA (convection-enhanced delivery, brain tumor), Sheba Medical Center/BioLineRx
    Click to Show/Hide
External Link
TTD: D02JIF
 Compound Name MIQ-004 Investigative [57]
Synonyms
M-IQ-004
    Click to Show/Hide
External Link
TTD: D01KZV
References
Ref 1 Epigenetically silenced lncRNA SNAI3-AS1 promotes ferroptosis in glioma via perturbing the m(6)A-dependent recognition of Nrf2 mRNA mediated by SND1. J Exp Clin Cancer Res. 2023 May 19;42(1):127. doi: 10.1186/s13046-023-02684-3.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317. doi: 10.1038/s41573-018-0008-x.
Ref 4 National Cancer Institute Drug Dictionary (drug id 756624).
Ref 5 New hope for dry AMD?. Nat Rev Drug Discov. 2013 Jul;12(7):501-2. doi: 10.1038/nrd4038.
Ref 6 Nitroxide pharmaceutical development for age-related degeneration and disease. Front Genet. 2015 Nov 6;6:325. doi: 10.3389/fgene.2015.00325. eCollection 2015.
Ref 7 The Keap1-Nrf2 pathway: promising therapeutic target to counteract ROS-mediated damage in cancers and neurodegenerative diseases. Biophys Rev. 2017 Feb;9(1):41-56. doi: 10.1007/s12551-016-0244-4. Epub 2016 Dec 6.
Ref 8 Clinical pipeline report, company report or official report of vTv Therapeutics.
Ref 9 Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016). Expert Opin Ther Pat. 2017 Jul;27(7):763-785. doi: 10.1080/13543776.2017.1325464. Epub 2017 May 10.
Ref 10 Clinical pipeline report, company report or official report of Aclipse Therapeutics.
Ref 11 The novel Nrf2 inducer TFM-735 ameliorates experimental autoimmune encephalomyelitis in mice. Eur J Pharmacol. 2017 May 5;802:76-84. doi: 10.1016/j.ejphar.2017.02.044. Epub 2017 Feb 27.
Ref 12 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 13 Photodynamic therapy: applications in atherosclerotic vascular disease with motexafin lutetium. Catheter Cardiovasc Interv. 2002 Nov;57(3):387-94.
Ref 14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7214).
Ref 15 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6800).
Ref 16 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6505).
Ref 17 Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. Shock. 2010 May;33(5):507-12.
Ref 18 ClinicalTrials.gov (NCT01436968) Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer. U.S. National Institutes of Health.
Ref 19 ClinicalTrials.gov (NCT00088400) Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors. U.S. National Institutes of Health.
Ref 20 ClinicalTrials.gov (NCT01280552) A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM). U.S. National Institutes of Health.
Ref 21 ClinicalTrials.gov (NCT00076986) The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme. U.S. National Institutes of Health.
Ref 22 ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.
Ref 23 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 24 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017222)
Ref 25 ClinicalTrials.gov (NCT05685004) Randomized Phase 2b Study of Safety And Efficacy Of TVI-Brain-1 Combined With Conformal Radiotherapy And Temozolomide Vs Standard Therapy In Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM). U.S.National Institutes of Health.
Ref 26 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 27 ClinicalTrials.gov (NCT05163080) Prospective Randomized Placebo-Controlled Trial of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE). U.S.National Institutes of Health.
Ref 28 ClinicalTrials.gov (NCT01472731) Safety and Imaging Study of GC1008 in Glioma. U.S. National Institutes of Health.
Ref 29 ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health.
Ref 30 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 31 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800037619)
Ref 32 Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.
Ref 33 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 34 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034046)
Ref 35 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029242)
Ref 36 ClinicalTrials.gov (NCT00062283) Alanosine in Treating Patients With Cancer. U.S. National Institutes of Health.
Ref 37 ClinicalTrials.gov (NCT01454596) CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII. U.S. National Institutes of Health.
Ref 38 Clinical pipeline report, company report or official report of Roche
Ref 39 ClinicalTrials.gov (NCT05460507) A Single Arm Open Label Study to Determine the Safety and Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Recurrence of Glioma in Patients Who Received a Prior Treatment With 186RNL. U.S.National Institutes of Health.
Ref 40 ClinicalTrials.gov (NCT04485949) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients With Glioblastoma. U.S.National Institutes of Health.
Ref 41 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026657)
Ref 42 Identification of an immunogenic CD8+ T-cell epitope derived from gamma-globin, a putative tumor-associated antigen for juvenile myelomonocytic leu... Blood. 2006 Oct 15;108(8):2662-8.
Ref 43 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800041844)
Ref 44 ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health.
Ref 45 ClinicalTrials.gov (NCT02541370) Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133
Ref 46 ClinicalTrials.gov (NCT01502917) Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. U.S. National Institutes of Health.
Ref 47 ClinicalTrials.gov (NCT00074646) Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas. U.S. National Institutes of Health.
Ref 48 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015264)
Ref 49 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017210)
Ref 50 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006625)
Ref 51 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 672).
Ref 52 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007949)
Ref 53 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000870)
Ref 54 Human IgG2 constant region enhances in vivo stability of anti-tenascin antibody 81C6 compared with its murine parent. Clin Cancer Res. 1998 Oct;4(10):2495-502.
Ref 55 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019960)
Ref 56 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
Ref 57 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.